Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2023-10-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于甲磺酸贝福替尼胶囊一线治疗适应症获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from 贝达药业股份有限公司 regarding the receipt of a drug registration certificate from the National Medical Products Administration (NMPA) for a new indication of a pharmaceutical product. It details the drug's registration, clinical research, and potential impact on the company. The document is an official announcement about regulatory approval and does not contain financial statements, earnings data, or detailed financial analysis. It is not a report, transcript, or presentation but a regulatory announcement about a product approval. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-10-12 Chinese
关于股东股份质押变动的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding changes in the pledge status of shares held by a major shareholder (宁波凯铭投资管理合伙企业) of 贝达药业股份有限公司. It details the number of shares pledged and released, the proportion of shares involved, and the impact on the company's control and operations. There is no financial statement, earnings data, or management discussion of financial results. The document is a regulatory disclosure about share pledge changes, which fits the category of Major Shareholding Notification (MRQ) as it involves significant share ownership changes and related pledge information. The document length is short (2289 characters), and it is not an announcement of a report publication but a direct disclosure. Therefore, the appropriate classification is MRQ with high confidence.
2023-09-28 Chinese
关于公司高级管理人员离职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management officer (Senior Vice President) of the company. It details the resignation date, the handover of responsibilities, and confirms that the resignation will not affect company operations. There is no financial data, no mention of financial results, or regulatory filings beyond the management change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-09-28 Chinese
关于CFT8919片药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Betta Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for the drug CFT8919 by the National Medical Products Administration (NMPA) in China. It details the clinical trial acceptance notice, background on the drug, and potential impacts and risks. The document is relatively short (1606 characters) and serves as an official announcement of a regulatory event rather than a financial report or detailed study. It does not contain financial data, management changes, voting results, or other report types defined in the filing categories. It is a regulatory announcement about a clinical trial acceptance, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-09-22 Chinese
关于股东股份质押变动的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding changes in the pledge status of shares held by a major shareholder (Ningbo Kaiming Investment Management Partnership) of Betta Pharmaceuticals Co., Ltd. It details the number of shares pledged, the extension of pledge periods, and assurances about the financial stability and control risks related to these pledges. The document does not contain financial statements, earnings data, or management discussion but focuses on share pledge changes by a controlling shareholder. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership or related shareholding matters such as pledges.
2023-09-15 Chinese
关于2021年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市的公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement from a company about the results of the first vesting period of a 2021 restricted stock incentive plan, including the number of shares vested, the number of participants, adjustments to the plan, and legal and financial confirmations. It includes specifics on stock grants, vesting conditions, performance targets, board approvals, and legal opinions. This type of document is a formal announcement related to share-based compensation and stock incentive plans, specifically about the vesting and listing of restricted shares. It is not a full annual or interim financial report, nor an earnings release or management discussion. It is also not a proxy statement or voting result announcement. The content focuses on the stock incentive plan's vesting results and related share issuance. According to the filing definitions, announcements about share issues or capital changes, including stock grants under incentive plans, fall under "Share Issue/Capital Change (SHA)". Therefore, this document should be classified as SHA with high confidence.
2023-09-14 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.